Amgen (AMGN) Tops Q2 EPS by 16c, Lifts FY Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/5/2026

1. PTC
2. NVDA
3. PCVX
4. META
5. MSFT
6. SPY
7. GMAB
8. USO
9. GOOGL
10. AMD

Go back to Amgen (AMGN) Tops Q2 EPS by 16c, Lifts FY Guidance

Amgen Reports Second Quarter 2017 Financial Results

July 25, 2017 4:01 PM EDT

THOUSAND OAKS, Calif., July 25, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the second quarter of 2017. Key results include:

Total revenues increased 2 percent versus the second quarter of 2016 to $5.8 billion. Product sales grew 2 percent driven by Prolia® (denosumab), Repatha® (evolocumab) and KYPROLIS® (carfilzomib). GAAP earnings per share (EPS) increased 18 percent to $2.91 driven by higher operating margins. GAAP operating income increased 13 percent to $2.7 billion and GAAP operating margin increased 4.9 percentage points to 48.4 percent. Non-GAAP EPS increased 15 percent to $3.27 driven by higher... More